Clarametyx Biosciences Strengthens Executive Leadership to Accelerate Clinical Development Efforts Clarametyx Biosciences, Inc. a clinical-stage biotechnology company developing immune-enabling therapies and vaccines to address biofilm-driven chronic respiratory disease, today announced two senior leadership positions within its executive team to support…
CorVista Health Demonstrates High-Sensitivity for Noninvasive Detection of CAD including INOCA (Ischemia with No Obstructed Coronary Arteries) at ACC.26 CorVista Health, a leader in noninvasive cardiovascular diagnostics, announced new data evaluating a physiologic signal–based machine-learning model for detecting cardiac ischemia.…
TruArc Partners Acquires North American Adhesives and Sealant Solutions Provider Matrix Adhesives Group TruArc Partners a private equity firm focused on middle-market investments in business services and specialty manufacturing, announced today that it has acquired Matrix Adhesives Group (“Matrix” or…
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session Corcept Therapeutics Incorporated a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the…
Bayer Crop Science Canada Redefines Canola Innovation With New “Advancing Better Canola” Initiative Bayer Crop Science Canada launches Advancing Better Canola (ABCs), an industry-wide initiative to challenge and redefine how it thinks about canola innovation in support of Canadian farmers.…
AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne Almirall S.A. a global biopharmaceutical company dedicated to medical dermatology, is presenting a broad range of clinical and real‑world data across its portfolio…
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group Turn Therapeutics, Inc. a clinical-stage dermatology company developing novel therapies for inflammatory skin diseases, today announced it has entered into a growth capital loan facility with Avenue…
The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ® The 15-20 National Hospital (l’Hôpital national des 15-20) in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME…
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy Coya Therapeutics, Inc. a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a…
Meiji Seika Pharma Co., Ltd. has announced the initiation of a Phase I clinical trial for ME3241, an innovative anti-PD-1 agonist monoclonal antibody developed through a research collaboration with the Foundation for Biomedical Research and Innovation at Kobe (FBRI). The…
Alvaro Grande Joins Burckhardt Compression as New Head of Services Burckhardt Compression has announced the appointment of Alvaro Grande as its new Head of Services, bringing over two decades of extensive experience in the compression industry. With a career spanning…
KCAS Bio’s Lyon Site Renews GLP Compliance, Strengthening Support for IND-Enabling Studies KCAS Bio has announced that its European bioanalytical facility in Lyon has successfully renewed its Statement of Compliance with Good Laboratory Practices (GLP). The renewal was granted in…